Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
E: info@sartorius.com
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,528
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,704.40 | 143.20 | -1.82% |
| CAC 40 | 7,158.91 | 231.79 | 3.35% |
| DAX 40 | 20,401.12 | 611.50 | 3.09% |
| Dow JONES (US) | 37,822.40 | 2,723.53 | -6.72% |
| FTSE 100 | 7,966.86 | 88.12 | -1.09% |
| HKSE | 20,127.68 | 2,722.13 | -11.91% |
| NASDAQ | 15,603.26 | 947.34 | -5.72% |
| Nikkei 225 | 33,012.58 | 768.00 | -2.27% |
| NZX 50 Index | 11,891.44 | 333.84 | -2.73% |
| S&P 500 | 5,041.94 | 20.31 | -0.40% |
| S&P/ASX 200 | 7,510.00 | 157.80 | -2.06% |
| SSE Composite Index | 3,145.55 | 48.97 | 1.58% |